IRITERO is contraindicated in patients with: A chronic inflammatory bowel disease and/or a bowel obstruction; A history of severe hypersensitivity reactions to Irinotecan Hydrochloride Trihydrate or to one of the excipients of IRITERO; In pregnant or breast feeding women; In patient with bilirubin > 3 times the ULN; In patient with a severe bone marrow failure; In patient presenting a risk factor, particularly those with a WHO performance status > 2.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
